Antiretroviral therapies for HIV, while extremely effective, need to be taken daily for life. Designing antibody treatments that need to be taken only once could improve compliance and reduce drug resistance.
Your genetic material instructs your cells to produce the proteins encoded in it.
Juan Gaertner/Science Photo Library via Getty Images
Gene therapies and vaccines are often injected into muscle cells that are inefficient at producing desired proteins. Making them work more like liver cells could lead to better treatment outcomes.
While pills come in many shapes and sizes, they all eventually reach your bloodstream and travel throughout your body.
Vadim Sazhniev/iStock via Getty Images
Tom Anchordoquy, University of Colorado Anschutz Medical Campus
From tablets and patches to ointments and infusions, the best way to deliver a drug is the one that gets the right amount to the right place.
Monaco and Japan have some of the highest life expectancies in the world. But calculating an individual’s life expectancy will require taking data analysis several steps further.
SHUTTERSTOCK
Predicting life expectancy remains in the realm of science fiction, but it may soon be possible. Are we prepared for such information? And who else would benefit from this knowledge?
Wozniacki struggled with unexplained symptoms before being diagnosed with rheumatoid arthritis in 2018.
Wu Hong/AAP
Biologics, therapies made inside or of living cells, are a growing share of pharmaceutical sales. But the cost of these miracle treatments makes them unaffordable for many. New FDA guidance may help.
Miniature biomanufacturing kits like this prototype could revolutionize the pharmaceutical industry.
Amino Labs
Small-batch brewers are starting to tinker with biologic drugs to meet their own medical needs. A side effect of their success would be a disruption to how big pharma makes and distributes drugs.
Protecting the patents of expensive medicines for longer would affect low-income countries.
Jason Reed/ReutersPics
Negotiators from 11 countries have been racing to resurrect the near-dead Trans-Pacific Partnership Agreement before the Asia-Pacific Economic Cooperation (APEC) summit this weekend.
The cells inside this bioreactor are the real pharmaceutical factories.
Sanofi Pasteur
What can Australia expect from the Trans-Pacific Partnership? We asked experts about to nominate some winners and losers.
Representatives of the 12 Trans-Pacific Partnership (TPP) member countries at a press conference in Atlanta, after a deal was reached.
EPA/Erik S. Lesser
Before the last round of negotiations, only a handful of issues remained in the way of concluding the TPP. A potential deal-breaker for Australia was intellectual property protections for biologics.
Trade minister Andrew Robb attends negotiations for the Trans Pacific Partnership in Sydney last year.
Dan Himbrechts/AAP Image
Over the next few weeks, the trade minister will be under intense pressure to renege on the government’s commitment to reject anything in the Trans Pacific Partnership that could undermine the PBS.
Insulin, which is used for controlling diabetes and has been in the market for 30 years, was the first biologic.
Yusmar Yahaya/Flickr
Biologics are widely accepted as the most effective way of treating certain diseases. They have become the fastest-growing class of therapeutic compounds, with about 300 now available for human use.
A group of oncologists have called on cancer patients to challenge the high prices charged by pharmaceutical companies for new cancer drugs.
ep_jhu/Flickr
Hope, fear, and desperation, along with the unique characteristics of the cancer drug market, create a “perfect storm” that continues to drive up prices for cancer drugs.
Research Fellow, NHMRC Centre for Research Excellence in the Social Determinants of Health Equity, School of Regulation and Global Governance, Australian National University